Imaging Agents for Inflammatory Components of Malignancy

恶性肿瘤炎症成分的显像剂

基本信息

  • 批准号:
    10226210
  • 负责人:
  • 金额:
    $ 25.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-15 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

SUMMARY FOR TR&D 3 TR&D 3 of the BTRC will develop imaging agents to detect inflammation and immunity, with a focus on small molecule PET agents to monitor immunotherapy, an increasing medical need. Inflammation has long been recognized as a promoter of tumor growth. More recently, harnessing innate and adaptive immunity to treat cancer through immune checkpoint inhibition and vaccines has captivated the community of cancer researchers and clinicians alike. We will develop and disseminate agents that address two different aspects of cancer and its relationships to inflammation and immunity, namely, checkpoint inhibition and complement. The immune checkpoint protein programmed death-ligand 1 (PD-L1) and its receptor PD-1 are preferred targets for cancer immunotherapy. PD-L1 is expressed by a variety of tumors, and its over-expression is induced in tumor cells to adapt to tumor infiltrating cytotoxic T cells. PD-L1 immunohistochemistry (IHC) is the best predictive biomarker for therapeutic monitoring of PD-L1/PD-1 targeted therapies. However, PD-L1 IHC is fraught with use of discordant antibodies, intra- and inter-tumoral heterogeneity of expression as well as limited bio-specimen availability such that we believe non-invasive imaging can help. Furthermore, despite the promise of immune checkpoint therapy, the majority of patients do not respond for reasons unclear. The complement system is central to recruiting inflammatory cells and promoting release of factors that can promote tumor growth and progression, confounding immunotherapy. We will synthesize, validate and disseminate agents targeting PD-L1 (Aim 1) and complement receptors C3aR and C5aR (Aim 2), which are bound by their cognate tumor-promoting anaphylatoxins. In Aim 3 we will validate – with correlation to post-imaging surgical tissue – a current BTRC lead PD-L1 imaging agent in patients undergoing immunotherapy for pancreas cancer through support from the Bloomberg-Kimmel Institute for Immunotherapy. Once validated in this ultimate fashion we will be confident to disseminate that agent for human studies elsewhere. TR&D 3 will also serve as the Clinical Validation Core, a hub that will disseminate not only valuable new human agents as noted above, but will also provide precursor and standard for other agents, allow cross-referencing of BTRC INDs and provide analysis to meet the evolving needs of the driving Collaborative Projects and service recipients.
TR & D 3摘要 BTRC的TR & D 3将开发成像剂来检测炎症和免疫,重点是小 分子PET试剂来监测免疫治疗,这是一个日益增长的医疗需求。长期以来,炎症一直是 被认为是肿瘤生长的促进剂。最近,利用先天和适应性免疫来治疗 通过免疫检查点抑制和疫苗来治疗癌症已经吸引了癌症研究人员的关注 和临床医生一样。我们将开发和传播针对癌症及其 与炎症和免疫的关系,即检查点抑制和补体。免疫 检查点蛋白程序性死亡配体1(PD-L1)及其受体PD-1是癌症的优选靶点 免疫疗法。PD-L1由多种肿瘤表达,其过表达在肿瘤细胞中被诱导, 适应肿瘤浸润的细胞毒性T细胞。PD-L1免疫组化(IHC)是最佳预测生物标志物 用于PD-L1/PD-1靶向治疗的治疗监测。然而,PD-L1 IHC充满了使用 不一致的抗体、肿瘤内和肿瘤间表达的异质性以及有限的生物样本 我们相信非侵入性成像可以提供帮助。此外,尽管承诺免疫 检查点治疗,大多数患者没有反应的原因不明。补体系统是 募集炎性细胞和促进因子释放的中心,这些因子可以促进肿瘤生长, 进展,混淆免疫治疗。我们将合成、验证和传播靶向PD-L1的药物 (Aim 1)和补体受体C3aR和C5aR(Aim 2),其通过其同源肿瘤促进因子结合。 过敏毒素在目标3中,我们将确认-与成像后手术组织相关-当前BTRC电极导线 PD-L1成像剂在接受胰腺癌免疫治疗的患者中的应用 Bloomberg-Kimmel免疫治疗研究所一旦以这种最终的方式得到验证,我们将有信心 将该药剂传播到其他地方进行人体研究。TR & D 3还将作为临床验证核心, 中心,不仅将传播如上所述有价值的新人类代理,而且还将提供前体 和其他药物的标准,允许BTRC IND的交叉引用,并提供分析,以满足不断发展的 推动合作项目和服务对象的需求。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTIN G POMPER其他文献

MARTIN G POMPER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTIN G POMPER', 18)}}的其他基金

Translational imaging biomarkers of the tumor microenvironment in early prostate cancer
早期前列腺癌肿瘤微环境的转化成像生物标志物
  • 批准号:
    10698133
  • 财政年份:
    2022
  • 资助金额:
    $ 25.79万
  • 项目类别:
Translational imaging biomarkers of the tumor microenvironment in early prostate cancer
早期前列腺癌肿瘤微环境的转化成像生物标志物
  • 批准号:
    10518916
  • 财政年份:
    2022
  • 资助金额:
    $ 25.79万
  • 项目类别:
Resource for Molecular Imaging Agents in Precision Medicine
精准医学分子成像剂资源
  • 批准号:
    10226206
  • 财政年份:
    2017
  • 资助金额:
    $ 25.79万
  • 项目类别:
Administration - Resource for Molecular Imaging Agents in Precision Medicine
管理 - 精准医学中分子成像剂的资源
  • 批准号:
    10226207
  • 财政年份:
    2017
  • 资助金额:
    $ 25.79万
  • 项目类别:
Training/Dissemination - Resource for Molecular Imaging Agents in Precision Medicine
培训/传播 - 精准医学分子成像剂资源
  • 批准号:
    10226214
  • 财政年份:
    2017
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    10594010
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    10411890
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    9886363
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    8671057
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    10092113
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了